Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Risk factors for clozapine discontinuation among 805 patients in the VA hospital system.

Moeller FG, Chen YW, Steinberg JL, Petty F, Ripper GW, Shah N, Garver DL.

Ann Clin Psychiatry. 1995 Dec;7(4):167-73.

PMID:
8721890
2.
3.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
4.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
5.

Substance abuse in schizophrenia: a review.

Buckley PF.

J Clin Psychiatry. 1998;59 Suppl 3:26-30. Review.

6.

Treatment-resistant schizophrenia--the role of clozapine.

Meltzer HY.

Curr Med Res Opin. 1997;14(1):1-20. Review.

PMID:
9524789
7.

Effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia.

Avnon M, Rabinowitz J.

Br J Psychiatry. 1995 Dec;167(6):760-4. Review.

PMID:
8829743
8.

[Hepatic tolerance of atypical antipsychotic drugs].

Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, Aubriot-Delmas B, Glikman J, Januel D.

Encephale. 2002 Nov-Dec;28(6 Pt 1):542-51. Review. French.

PMID:
12506267
9.
Items per page

Supplemental Content

Write to the Help Desk